Marker Therapeutics Inc (MRKR) - Total Liabilities
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has total liabilities worth $3.35 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Marker Therapeutics Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Marker Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See MRKR working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Marker Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Marker Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Passage Bio Inc
NASDAQ:PASG
|
USA | $43.04 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
USA | $238.96 Million |
|
Mitchells & Butlers PLC
LSE:MAB
|
UK | GBX2.64 Billion |
|
Monami
KO:005360
|
Korea | ₩95.33 Billion |
|
Hands Corporation Ltd
KO:143210
|
Korea | ₩674.40 Billion |
|
SenzaGen AB
ST:SENZA
|
Sweden | Skr24.13 Million |
|
Dynamic Metals Ltd
AU:DYM
|
Australia | AU$793.85K |
|
Telcon Inc
KQ:200230
|
Korea | ₩47.85 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Marker Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MRKR market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marker Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marker Therapeutics Inc (1999–2024)
The table below shows the annual total liabilities of Marker Therapeutics Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.46 Million | +12.67% |
| 2023-12-31 | $3.07 Million | -79.25% |
| 2022-12-31 | $14.82 Million | -38.63% |
| 2021-12-31 | $24.15 Million | +32.18% |
| 2020-12-31 | $18.27 Million | +703.77% |
| 2019-12-31 | $2.27 Million | -18.92% |
| 2018-12-31 | $2.80 Million | +84.17% |
| 2017-12-31 | $1.52 Million | -12.35% |
| 2016-12-31 | $1.74 Million | -93.80% |
| 2015-12-31 | $28.01 Million | +2143.90% |
| 2014-12-31 | $1.25 Million | -85.89% |
| 2013-12-31 | $8.85 Million | +53.27% |
| 2012-12-31 | $5.77 Million | +51.84% |
| 2011-12-31 | $3.80 Million | +12.15% |
| 2010-12-31 | $3.39 Million | +243.58% |
| 2009-12-31 | $986.35K | -67.94% |
| 2008-12-31 | $3.08 Million | +57.44% |
| 2007-12-31 | $1.95 Million | -38.06% |
| 2006-12-31 | $3.15 Million | +36.58% |
| 2005-12-31 | $2.31 Million | -8.65% |
| 2004-12-31 | $2.53 Million | +243.08% |
| 2003-12-31 | $736.95K | +149.31% |
| 2002-12-31 | $295.60K | +70.84% |
| 2001-12-31 | $173.03K | -74.66% |
| 2000-12-31 | $682.74K | +135.66% |
| 1999-12-31 | $289.71K | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-assoc… Read more